LU92338I2 - Enzalutamide et ses sels pharmaceutiquement acceptables (XTANDI) - Google Patents

Enzalutamide et ses sels pharmaceutiquement acceptables (XTANDI) Download PDF

Info

Publication number
LU92338I2
LU92338I2 LU92338C LU92338C LU92338I2 LU 92338 I2 LU92338 I2 LU 92338I2 LU 92338 C LU92338 C LU 92338C LU 92338 C LU92338 C LU 92338C LU 92338 I2 LU92338 I2 LU 92338I2
Authority
LU
Luxembourg
Prior art keywords
xtandi
enzalutamide
pharmaceutically acceptable
acceptable salts
synthesizing
Prior art date
Application number
LU92338C
Other languages
English (en)
French (fr)
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37431537&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92338(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Publication of LU92338I2 publication Critical patent/LU92338I2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/16—Isothiocyanates
    • C07C331/28—Isothiocyanates having isothiocyanate groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
LU92338C 2005-05-13 2013-12-17 Enzalutamide et ses sels pharmaceutiquement acceptables (XTANDI) LU92338I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68083505P 2005-05-13 2005-05-13
US75035105P 2005-12-15 2005-12-15
US75655206P 2006-01-06 2006-01-06
PCT/US2006/011417 WO2006124118A1 (en) 2005-05-13 2006-03-29 Diarylhydantoin compounds

Publications (1)

Publication Number Publication Date
LU92338I2 true LU92338I2 (fr) 2015-10-27

Family

ID=37431537

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92338C LU92338I2 (fr) 2005-05-13 2013-12-17 Enzalutamide et ses sels pharmaceutiquement acceptables (XTANDI)

Country Status (28)

Country Link
EP (5) EP3970721A1 (ko)
JP (11) JP4644737B2 (ko)
KR (11) KR102020721B1 (ko)
CN (5) CN101222922B (ko)
AT (1) ATE541571T1 (ko)
AU (1) AU2006248109B2 (ko)
BR (1) BRPI0610359B8 (ko)
CA (1) CA2608436C (ko)
CY (2) CY1112798T1 (ko)
DK (2) DK1893196T4 (ko)
ES (2) ES2378778T5 (ko)
HK (3) HK1112856A1 (ko)
HR (2) HRP20120323T4 (ko)
HU (1) HUS1300076I1 (ko)
IL (3) IL187328A (ko)
LU (1) LU92338I2 (ko)
ME (1) ME01992B (ko)
MX (4) MX346924B (ko)
NO (4) NO339997B1 (ko)
NZ (3) NZ591119A (ko)
PL (2) PL2444085T3 (ko)
PT (2) PT2444085E (ko)
RS (2) RS53967B1 (ko)
RU (3) RU2448096C3 (ko)
SG (1) SG10201703816SA (ko)
SI (2) SI2444085T1 (ko)
WO (1) WO2006124118A1 (ko)
ZA (2) ZA200710870B (ko)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE502298T1 (de) 2003-12-19 2011-04-15 Univ California Verfahren und materialien zur beurteilung von prostatakrebstherapien
NZ550102A (en) 2004-02-24 2010-10-29 Univ California Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
NZ591119A (en) * 2005-05-13 2012-08-31 Univ California Use of diarylhydantoin compounds for treating specific cancers
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
PL2004181T6 (pl) 2006-03-27 2023-09-04 The Regents Of The University Of California Modulator receptorów androgenowych do leczenia raka prostaty i chorób powiązanych z receptorami androgenowymi
CA2648139A1 (en) * 2006-03-29 2007-11-08 The Regents Of The University Of California Diaryl thiohydantoin compounds and their use in the treatment of hyperproliferative disorders
TW200846338A (en) * 2007-02-01 2008-12-01 Chugai Pharmaceutical Co Ltd Pyridyl imidazolidine derivative having sulfamoyl group, and pharmaceutical use thereof
WO2008119015A2 (en) * 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
UY31432A1 (es) * 2007-10-26 2009-05-29 Compuestos de diarilhidantoina
CA2753425A1 (en) * 2009-02-24 2010-09-02 Medivation Prostate Therapeutics, Inc. Specific diarylhydantoin and diarylthiohydantoin compounds
CN101817787B (zh) * 2009-02-26 2013-07-24 童友之 抗前列腺癌的雄性激素受体拮抗剂
US8778621B2 (en) * 2009-05-12 2014-07-15 Koninklijke Philips N.V. Phosphodiesterase 4D7 as marker for malignant, hormone-sensitive prostate cancer
WO2011029392A1 (en) * 2009-09-10 2011-03-17 Youzhi Tong Androgen receptor antagonists and uses thereof
EP2475366A1 (en) 2009-09-11 2012-07-18 Bayer Pharma Aktiengesellschaft Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
MX2012006615A (es) 2009-12-11 2012-10-05 Autifony Therapeuticts Ltd Derivados de imidazolidinodiona.
US9108944B2 (en) 2010-02-16 2015-08-18 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
HUE038637T2 (hu) 2010-02-24 2018-12-28 Medivation Prostate Therapeutics Llc Eljárás a diaril-tiohidantoin és a diaril-hidantoin vegyületek szintetizálására
RU2434851C1 (ru) * 2010-07-22 2011-11-27 Александр Васильевич Иващенко Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
EP2649066B1 (en) 2010-12-06 2015-10-21 Autifony Therapeutics Limited Hydantoin derivatives useful as kv3 inhibitors
EP2683694B1 (en) * 2011-03-10 2016-04-27 Suzhou Kintor Pharmaceuticals, Inc. Androgen receptor antagonists and uses thereof
ES2541295T3 (es) 2011-04-21 2015-07-17 Orion Corporation Carboxamidas que modulan el receptor de andrógenos
US9193704B2 (en) 2011-06-07 2015-11-24 Autifony Therapeutics Limited Hydantoin derivatives as KV3 inhibitors
BR112014002200A2 (pt) * 2011-07-29 2017-03-07 Medivation Prostate Therapeutics Inc tratamento de câncer de mama
DK2785349T4 (da) 2011-11-30 2023-01-09 Astrazeneca Ab Kombinationsbehandling af cancer
CN103159680A (zh) * 2011-12-14 2013-06-19 爱美尼迪药物有限公司 咪唑二酮类化合物及其用途
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
WO2013175215A1 (en) 2012-05-22 2013-11-28 Autifony Therapeutics Limited Triazoles as kv3 inhibitors
JP2015517563A (ja) 2012-05-22 2015-06-22 アウトイフオンイ トヘラペウトイクス リミテッド Ｋｖ３阻害剤としてのヒダントイン誘導体
LT2894151T (lt) * 2012-09-04 2021-09-10 Shanghai Hengrui Pharmaceutical Co. Ltd. Imidazolino dariniai, jų gamybos būdai ir jų naudojimas medicinoje
CA2884640A1 (en) * 2012-09-11 2014-03-20 Dr. Reddy's Laboratories Limited Enzalutamide polymorphic forms and its preparation
IN2015DN02875A (ko) * 2012-09-11 2015-09-11 Medivation Prostate Therapeutics Inc
EA030128B1 (ru) 2012-09-26 2018-06-29 Арагон Фармасьютикалз, Инк. Способ лечения неметастатического кастрационно-резистентного рака простаты
US9944607B2 (en) 2012-10-16 2018-04-17 Whitehead Institute For Biomedical Research Thiohydantoin derivatives and uses thereof
CA2889756C (en) * 2012-10-26 2023-03-14 Memorial Sloan-Kettering Cancer Center Thiohydantoin compounds as androgen receptor modulators
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
RU2520134C1 (ru) * 2013-02-27 2014-06-20 Общество с ограниченной ответственностью "Авионко" (ООО "Авионко") Замещенные (r)-3-(4-метилкарбамоил-3-фторфениламино)-тетрагидро-фуран-3-енкарбоновые кислоты и их эфиры, способ их получения и применения
WO2014167428A2 (en) * 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
EP3010889B1 (de) 2013-06-20 2018-10-03 Bayer CropScience Aktiengesellschaft Arylsulfid- und arylsulfoxid-derivate als akarizide und insektizide
CN104341396A (zh) * 2013-08-08 2015-02-11 上海医药集团股份有限公司 二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用
WO2015042170A1 (en) 2013-09-17 2015-03-26 Wayne State University Compositions and uses of combinations of dim-related indoles and selected anti-androgen compounds
WO2015042029A1 (en) * 2013-09-19 2015-03-26 Glaxosmithkline Llc Combination drug therapy
CN106543085A (zh) * 2013-10-14 2017-03-29 杭州普晒医药科技有限公司 恩杂鲁胺的固态形式及其制备方法和用途
US20160251316A1 (en) 2013-10-31 2016-09-01 Sun Pharmaceutical Industries Limited Process for the preparation of enzalutamide
WO2015092617A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Processes and intermediates for the preparation of enzalutamide
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CN104803919A (zh) * 2014-01-26 2015-07-29 上海医药工业研究院 用于制备恩杂鲁胺中间体的方法
WO2015121768A1 (en) 2014-02-13 2015-08-20 Ranbaxy Laboratories Limited Process for the preparation of enzalutamide
CZ2014232A3 (cs) 2014-04-07 2015-10-14 Zentiva, K.S. Způsob výroby enzalutamidu
CN103896847B (zh) * 2014-04-09 2016-01-20 沈江 一种非甾体类抗雄激素化合物及其制备方法和应用
CN103910679B (zh) * 2014-04-23 2016-05-25 杭州新博思生物医药有限公司 一种恩杂鲁胺的制备方法
CN104003939B (zh) * 2014-06-06 2017-07-07 山东大学 二芳基取代乙内酰硫脲类化合物及其制备方法与应用
CN104016924B (zh) * 2014-06-16 2016-04-13 上海鼎雅药物化学科技有限公司 一种“一锅法”合成恩杂鲁胺的方法
WO2015196144A2 (en) 2014-06-20 2015-12-23 England Pamela M Androgen receptor antagonists
RU2557235C1 (ru) * 2014-07-08 2015-07-20 Александр Васильевич Иващенко Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты
US20170190670A1 (en) * 2014-07-11 2017-07-06 Shilpa Medicare Limited Improved process for the preparation of enzalutamide
RU2017120330A (ru) 2014-12-12 2019-01-14 Медивэйшн Простейт Терапьютикс, Ллс Способ прогнозирования ответа на терапевтические агенты для лечения рака молочной железы и способ лечения рака молочной железы
CN104610111A (zh) * 2014-12-26 2015-05-13 杭州和泽医药科技有限公司 一种4-异硫代氰酰基-2-(三氟甲基)苯甲腈的制备方法
CN105523958B (zh) * 2015-01-13 2017-11-03 北京海步医药科技股份有限公司 一种制备二芳基硫代乙内酰脲衍生物关键中间体的方法
CN106187905B (zh) * 2015-05-05 2020-02-21 北京海步医药科技股份有限公司 丁鲁他胺的结晶形式及其制备方法
ITUB20151256A1 (it) 2015-05-28 2016-11-28 Olon Spa Processo industriale per la preparazione di enzalutamide
ITUB20151311A1 (it) * 2015-05-28 2016-11-28 Olon Spa Procedimento per la preparazione di enzalutamide
ITUB20151204A1 (it) 2015-05-28 2016-11-28 Olon Spa Procedimento per la preparazione di enzalutamide
CA2987563A1 (en) * 2015-05-29 2016-12-08 Astellas Pharma Inc. Production method of enzalutamide crystal form
DK3348546T3 (da) * 2015-09-10 2020-07-06 Jiangsu Hengrui Medicine Co Krystallinsk form af androgenreceptorinhibitor og fremgangsmåde til fremstilling deraf
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
EP3481394A1 (en) * 2016-07-08 2019-05-15 Janssen Pharmaceutica N.V. Thiohydantoin androgen receptor antagonists for the treatment of cancer
AU2017376704B2 (en) 2016-12-16 2021-08-05 Kangpu Biopharmaceuticals, Ltd. Composition, application thereof and treatment method
EP3616696A4 (en) 2017-04-28 2021-01-27 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION CONTAINING ENZALUTAMIDE WHICH MAY BE ADMINISTERED ORALLY
AU2018351714A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
US10513504B2 (en) 2018-03-08 2019-12-24 Apotex Inc. Processes for the preparation of apalutamide and intermediates thereof
CZ2018234A3 (cs) 2018-05-21 2019-12-04 Zentiva Ks Zvýšení rozpustnosti a biodostupnosti enzalutamidu
CN108976171B (zh) * 2018-08-27 2020-06-16 长沙泽达医药科技有限公司 化合物、组合物及其在药物制备中的用途
JP2022509917A (ja) 2018-11-05 2022-01-25 ファイザー・インク がんを処置するための組合せ
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11292782B2 (en) 2018-11-30 2022-04-05 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
CN109796437B (zh) * 2019-02-26 2021-08-24 上海健康医学院 具有ar和hdac双重抑制作用的乙内酰脲类和乙内酰硫脲类化合物及用途
CA3143111A1 (en) 2019-06-27 2020-12-30 Synthon B.V. Process for preparation of enzalutamide
CN110452166A (zh) * 2019-09-06 2019-11-15 浙江朗华制药有限公司 一种5-异硫氰酰基-3-三氟甲基-2-氰基吡啶的制备方法
US20220347102A1 (en) 2019-10-03 2022-11-03 Synthon B.V. Pharmaceutical composition comprising enzalutamide
WO2021240206A1 (en) 2020-05-24 2021-12-02 Lotus International Pte. Ltd. Enzalutamide formulation
MX2023001823A (es) 2020-08-13 2023-03-13 Pfizer Terapia de combinacion.
CA3201054A1 (en) 2020-12-11 2022-06-16 Yoon-Suk Lee Novel compounds as androgen receptor and phosphodiesterase dual inhibitor
CA3214316A1 (en) 2021-03-24 2022-09-29 Pfizer Inc. Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
EP4112603A1 (en) 2021-06-29 2023-01-04 Química Sintética, S.A. Processes for the preparation of non-steroidal antiandrogens
KR20230052759A (ko) 2021-10-13 2023-04-20 주식회사 엘지에너지솔루션 배터리 충방전 프로파일 분석 방법 및 배터리 충방전 프로파일 분석 장치
CN114181155A (zh) * 2021-12-21 2022-03-15 上海朝晖药业有限公司 碘-恩杂鲁胺及其制备方法及其应用
CN117164520A (zh) * 2022-01-28 2023-12-05 南京思聚生物医药有限公司 一种局部作用的雄激素受体拮抗剂及其应用
KR20230170859A (ko) 2022-06-11 2023-12-19 이태영 패스트칫솔
CN115850186B (zh) * 2023-02-07 2024-04-09 长沙泽达医药科技有限公司 一种乙撑硫脲衍生物的晶型及用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2329276A1 (fr) 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2694290B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2715402B1 (fr) * 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
WO1995019770A1 (en) † 1994-01-21 1995-07-27 Sepracor, Inc. Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
FR2725206B1 (fr) 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
FR2741342B1 (fr) 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
BR9914018A (pt) 1998-09-22 2001-07-03 Yamanouchi Pharmaceuticals Co Derivado de cianofenila
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
JP2006510600A (ja) 2002-10-04 2006-03-30 ラボラトワール フルニエ エス・アー ２−チオヒダントインに由来する化合物及び治療におけるその使用
FR2850652B1 (fr) 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US20050005529A1 (en) 2003-07-10 2005-01-13 David Brault Lighting system for a greenhouse
NZ550102A (en) * 2004-02-24 2010-10-29 Univ California Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
AU2005280908A1 (en) 2004-09-09 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Novel imidazolidine derivative and use thereof
NZ591119A (en) * 2005-05-13 2012-08-31 Univ California Use of diarylhydantoin compounds for treating specific cancers
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds

Also Published As

Publication number Publication date
CA2608436C (en) 2015-03-24
HK1217103A1 (zh) 2016-12-23
NO20180225A1 (no) 2008-02-08
MX2007014132A (es) 2008-04-09
SI1893196T2 (sl) 2015-10-30
KR20140041831A (ko) 2014-04-04
JP2015098497A (ja) 2015-05-28
KR102020721B1 (ko) 2019-09-10
IL187328A (en) 2016-02-29
SI2444085T1 (sl) 2015-06-30
KR20120102140A (ko) 2012-09-17
KR101515335B1 (ko) 2015-04-24
CN116003328A (zh) 2023-04-25
JP2018100292A (ja) 2018-06-28
CN105037273A (zh) 2015-11-11
HUS1300076I1 (hu) 2013-12-17
NO342490B1 (no) 2018-06-04
KR101782236B1 (ko) 2017-09-26
BRPI0610359B8 (pt) 2021-05-25
MX346924B (es) 2017-04-05
KR20170107585A (ko) 2017-09-25
DK1893196T4 (en) 2015-10-19
WO2006124118A1 (en) 2006-11-23
RU2448096C2 (ru) 2012-04-20
RU2638833C2 (ru) 2017-12-18
ZA201201793B (en) 2015-12-23
KR20190104244A (ko) 2019-09-06
BRPI0610359A2 (pt) 2010-06-15
EP3106162A1 (en) 2016-12-21
SI1893196T1 (sl) 2012-06-29
JP5150780B2 (ja) 2013-02-27
EP3970721A1 (en) 2022-03-23
AU2006248109A1 (en) 2006-11-23
HRP20120323T4 (hr) 2015-10-09
ES2535179T3 (es) 2015-05-06
ES2378778T5 (es) 2015-09-25
SG10201703816SA (en) 2017-06-29
MX2022009759A (es) 2022-09-05
ES2378778T3 (es) 2012-04-17
NO2017019I2 (no) 2017-05-04
AU2006248109B2 (en) 2012-11-15
KR20110041580A (ko) 2011-04-21
HK1112856A1 (en) 2008-09-19
NZ591119A (en) 2012-08-31
KR101332924B1 (ko) 2013-11-26
IL243812A0 (en) 2016-04-21
CN110003114B (zh) 2023-01-17
EP1893196B2 (en) 2015-07-29
JP2019218352A (ja) 2019-12-26
HK1169321A1 (en) 2013-01-25
PT1893196E (pt) 2012-04-03
RS52274B (en) 2012-10-31
JP2022101657A (ja) 2022-07-06
CN101222922A (zh) 2008-07-16
PL1893196T3 (pl) 2012-06-29
EP1893196A1 (en) 2008-03-05
KR102481886B1 (ko) 2022-12-28
CN110003114A (zh) 2019-07-12
JP2012236843A (ja) 2012-12-06
JP2012211190A (ja) 2012-11-01
PL1893196T5 (pl) 2015-12-31
DK1893196T3 (da) 2012-04-10
MX2019015200A (es) 2020-02-05
PT2444085E (pt) 2015-06-11
RU2017142159A (ru) 2019-06-05
BRPI0610359B1 (pt) 2020-09-24
RU2448096C3 (ru) 2017-12-11
HRP20120323T1 (en) 2012-05-31
EP1893196B1 (en) 2012-01-18
ME01992B (me) 2012-10-30
ATE541571T1 (de) 2012-02-15
KR20130060369A (ko) 2013-06-07
KR20230003445A (ko) 2023-01-05
JP5138753B2 (ja) 2013-02-06
CN102584712A (zh) 2012-07-18
CY2013047I1 (el) 2015-11-04
IL187328A0 (en) 2008-04-13
CA2608436A1 (en) 2006-11-23
KR20150086567A (ko) 2015-07-28
CN105037273B (zh) 2019-04-19
KR102324567B1 (ko) 2021-11-09
KR101579701B1 (ko) 2015-12-22
NZ710355A (en) 2017-01-27
PL2444085T3 (pl) 2015-07-31
NO2017019I1 (no) 2017-05-04
CN101222922B (zh) 2012-04-18
KR20080014039A (ko) 2008-02-13
JP2011068653A (ja) 2011-04-07
NO20161996A1 (no) 2008-02-08
CY2013047I2 (el) 2015-11-04
HRP20150437T1 (en) 2015-06-05
KR101431407B1 (ko) 2014-08-18
NO20076401L (no) 2008-02-08
EP2444085A1 (en) 2012-04-25
JP4644737B2 (ja) 2011-03-02
ZA200710870B (en) 2012-06-27
JP2023075313A (ja) 2023-05-30
RS52274B2 (sr) 2018-05-31
JP6013535B2 (ja) 2016-10-25
RU2007146462A (ru) 2009-06-20
DK2444085T3 (en) 2015-04-27
EP1893196A4 (en) 2009-03-18
NZ564223A (en) 2011-03-31
IL258880A (en) 2018-06-28
EP2561871A1 (en) 2013-02-27
KR101332889B1 (ko) 2013-11-26
KR20210136161A (ko) 2021-11-16
JP2021035970A (ja) 2021-03-04
EP2444085B1 (en) 2015-03-18
NO339997B1 (no) 2017-02-27
KR101169832B1 (ko) 2012-07-30
RS53967B1 (en) 2015-08-31
CY1112798T1 (el) 2015-11-04
KR20140141676A (ko) 2014-12-10
JP2016183200A (ja) 2016-10-20
JP2008540523A (ja) 2008-11-20

Similar Documents

Publication Publication Date Title
LU92338I2 (fr) Enzalutamide et ses sels pharmaceutiquement acceptables (XTANDI)
NO2020031I1 (no) kobimetinib, inklusive farmasøytisk akseptable salter og solvater, særlig kobimetinib hemifumarat
SG170809A1 (en) Diarylthiohydantoin compounds
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
UA96742C2 (en) Mek inhibitors and use thereof
EA201990219A3 (ru) Ингибиторы mek и способы их применения